Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Applied Dna Scns
(NQ:
APDN
)
3.630
-0.120 (-3.20%)
Streaming Delayed Price
Updated: 3:59 PM EDT, May 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Applied Dna Scns
< Previous
1
2
3
4
Next >
Applied DNA Reports First Quarter Fiscal 2023 Financial Results
February 09, 2023
From
Applied DNA Sciences, Inc.
Via
Business Wire
Applied DNA to Report First Quarter Fiscal 2023 Financial Results and Host Investor Conference Call and Webcast on Thursday, February 9, 2023
February 02, 2023
From
Applied DNA Sciences, Inc.
Via
Business Wire
Applied DNA Announces Publication of Peer-Reviewed Journal Article Validating Potential Use of linearDNA™ as a New Class of DNA-Based Vaccines
January 05, 2023
From
Applied DNA Sciences, Inc.
Via
Business Wire
Applied DNA Announces Fourth Quarter and Fiscal Year 2022 Financial Results
December 14, 2022
From
Applied DNA Sciences, Inc.
Via
Business Wire
Applied DNA to Report Fiscal 2022 Fourth Quarter and Year End Financial Results on December 14, 2022
December 12, 2022
From
Applied DNA Sciences, Inc.
Via
Business Wire
Applied DNA to Establish North America’s First Enzymatic (Cell Free) Large-Scale cGMP DNA Manufacturing Capacity in Suffolk County, New York
October 24, 2022
From
Applied DNA Sciences, Inc.
Via
Business Wire
Applied DNA Sciences (NASDAQ: APDN) Receives Largest Purchase Order for LinearDNA Valued Over Mid-Six-Figures
October 10, 2022
Applied DNA Sciences, Inc. (NASDAQ: APDN) is engaged as a biotechnology company, which is focused on developing PCR-based DNA technologies.
Via
Spotlight Growth
Applied DNA Announces Receipt of Largest Single Purchase Order for LinearDNA™ To-Date
October 10, 2022
From
Applied DNA Sciences, Inc.
Via
Business Wire
Applied DNA’s Biotherapeutics Subsidiary Publishes Manuscript Demonstrating that a LinearDNA™ Vaccine Candidate was Protective in Virus Challenge Trial in Ferrets
September 30, 2022
From
Applied DNA Sciences, Inc.
Via
Business Wire
Applied DNA and the Cornell University College of Veterinary Medicine Announce Research Collaboration to Accelerate Application of LinearDNA™ Platform for Veterinary Health Applications
September 08, 2022
From
Applied DNA Sciences, Inc.
Via
Business Wire
Applied DNA to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 12-14, 2022
September 07, 2022
From
Applied DNA Sciences, Inc.
Via
Business Wire
Applied DNA Launches Monkeypox Testing Service
September 06, 2022
From
Applied DNA Sciences, Inc.
Via
Business Wire
Applied DNA Submits PCR-based Monkeypox Virus Diagnostic Test for Approval to New York State Department of Health
August 19, 2022
From
Applied DNA Sciences, Inc.
Via
Business Wire
Investors Benefit as Healthtech Comes Into Focus (VERU, APDN, TOMDF, DNA, SYBX)
August 16, 2022
Via
AB Newswire
Applied DNA Reports Third Quarter Fiscal 2022 Financial Results
August 11, 2022
From
Applied DNA Sciences, Inc.
Via
Business Wire
Applied DNA Biotherapeutics Subsidiary Reports LinearDNA™ Platform Development Milestone: First Successful Administration of LinearDNA In Vivo via Lipid Nanoparticles (LNP)
August 10, 2022
From
Applied DNA Sciences, Inc.
Via
Business Wire
Applied DNA Awarded Extension of Health Services Contract with The City University of New York
August 09, 2022
From
Applied DNA Sciences, Inc.
Via
Business Wire
Applied DNA Receives Approximately $3.6 Million in Net Proceeds from Warrant Exercise
August 09, 2022
From
Applied DNA Sciences
Via
Business Wire
Applied DNA to Host Conference Call and Webcast Discussing Fiscal 2022 Third Quarter Results and Corporate Updates
August 08, 2022
From
Applied DNA Sciences, Inc.
Via
Business Wire
Applied DNA Announces Closing of Upsized $12 Million Public Offering
August 08, 2022
From
Applied DNA Sciences, Inc.
Via
Business Wire
Applied DNA Announces Pricing of $12 Million Upsized Public Offering, Priced at a Premium to Market Under Nasdaq Rules
August 04, 2022
From
Applied DNA Sciences, Inc.
Via
Business Wire
Applied DNA Sciences (NASDAQ: APDN) Begins Validation Testing of its Monkeypox Virus PCR Diagnostic Test
August 02, 2022
Applied DNA Sciences, Inc. (NASDAQ: APDN) is a biotechnology company that is focused on producing and developing polymerase chain reaction
Via
Spotlight Growth
Topics
Economy
Exposures
COVID-19
Supply Chain
Applied DNA Initiates Analytical Validation of PCR-based Diagnostic Test Specific to Monkeypox Virus
August 02, 2022
From
Applied DNA Sciences, Inc.
Via
Business Wire
Applied DNA Biotherapeutics Subsidiary LineaRx and EvviVax Publish Additional Positive Animal Proof-of-Concept Data Supporting LinearDNA™ Platform as a Unique Approach to Veterinary DNA Vaccine Development
July 25, 2022
From
Applied DNA Sciences, Inc.
Via
Business Wire
Applied DNA Biotherapeutics Subsidiary LineaRx to Present Data Showcasing Advantages of its Enzymatically Produced LinearDNA as Substitute for Plasmid DNA in IVT mRNA Production at the 2nd Annual mRNA-Based Therapeutics Summit
July 22, 2022
From
Applied DNA Sciences, Inc.
Via
Business Wire
Applied DNA Launches Initiatives to Expand Awareness of LinearDNA™ Platform as an Alternative to Plasmid DNA for Therapeutic Applications, Revamps LineaRx Website
June 29, 2022
From
Applied DNA Sciences, Inc.
Via
Business Wire
U.S. Government Guidance Permits DNA Traceability and Isotopic Testing as Evidence under Uyghur Forced Labor Prevention Act
June 21, 2022
From
Applied DNA Sciences, Inc.
Via
Business Wire
Applied DNA and EvviVax Announce Peer-Reviewed Publication of Positive Preclinical Data for LinearDNA™ Platform as a Novel Cancer Vaccine Strategy in the Journal of Experimental & Clinical Cancer Research
June 06, 2022
From
Applied DNA Sciences, Inc.
Via
Business Wire
Applied DNA Reports Second Quarter Fiscal 2022 Financial Results
May 12, 2022
From
Applied DNA Sciences, Inc.
Via
Business Wire
Applied DNA Schedules Fiscal 2022 Second Quarter Financial Results Conference Call and Webcast for Thursday, May 12, 2022
May 09, 2022
From
Applied DNA Sciences, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.